After months of laboratory work and successful testing in rhesus macaque monkeys, researchers at Johnson & Johnson and Beth Israel Deaconess Medical center are now looking for 60,000 people to participate in Phase 3 trials. Read Article
A COVID-19 vaccine developed by Johnson & Johnson in partnership with Beth Israel Deaconess Medical Center has now entered its final stage of clinical trials, making it the fourth American company to reach that step. Watch interview
The company will become the first to test the simpler regimen of its candidate which is being developed by Janssen Pharmaceutical Companies, Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, told FOX Business. Read Article
Unlike some of its competitors, Johnson & Johnson’s vaccine does not need to be frozen and may require just one shot instead of two. Read Article
“The benefits of a single-shot vaccine are potentially profound in terms of mass immunization campaigns and global pandemic control,” Dr. Dan Barouch. Read Article
Up to 60,000 volunteers, including some in Boston, will take part in the trial following encouraging data from more limited testing. Read Article
Three other candidates have a head start, but J&J’s vaccine could be easier to administer and distribute if it is proved safe and effective. Read Article
ABCNEWS
foxbusiness
NYT
Boston Globe